Mibolerone
From Wikipedia, the free encyclopedia
|
Mibolerone
|
|
| Systematic (IUPAC) name | |
| (7R,8R,9S,10R,13S,14S,17S)-17-Hydroxy- 7,13,17-trimethyl-1,2,6,7,8,9,10,11,1
2,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C20H30O2 |
| Mol. mass | 302.4558 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | 2-4 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule 3 (US) |
| Routes | Oral |
Mibolerone is a potent anabolic steroid which is both higher affinity[1] and more selective[2] for the androgen receptor than metribolone.
[edit] References
- ^ Murthy LR, Johnson MP, Rowley DR, Young CY, Scardino PT, Tindall DJ (1986). "Characterization of steroid receptors in human prostate using mibolerone". Prostate 8 (3): 241–53. PMID 2422638.
- ^ Schilling K, Liao S (1984). "The use of radioactive 7 alpha, 17 alpha-dimethyl-19-nortestosterone (mibolerone) in the assay of androgen receptors". Prostate 5 (6): 581–8. PMID 6333679.
|
||||||||

